Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Financial Implications - The merger allowed Bain Capital to gain over $120 million from shares purchased at the depressed offering price [3]. - Cerevel's January 18, 2024, Proxy statement is claimed to have misled investors regarding the timing and nature of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, is accused of acquiring shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Financial Implications - The merger allowed Bain Capital to gain over $120 million from shares purchased at the depressed offering price [3]. - Cerevel's January 18, 2024, Proxy statement allegedly misled investors about the timing and nature of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which impacted the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger was announced [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - Cerevel's January 18, 2024 Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost or obligation to participate [3] - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3] Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [4] - The firm seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [4]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. on behalf of investors who sold or held shares during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit covers individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - Allegations include that Bain Capital and Pfizer orchestrated a secondary stock offering to allow Bain to acquire shares at a discounted price before AbbVie’s acquisition announcement [5] - The acquisition by AbbVie was announced at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Legal Representation - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - A lead plaintiff must be appointed by June 3, 2025, to represent the interests of the class members [1][3]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for alleged violations of securities laws, specifically related to misleading statements made during a secondary stock offering and a proxy statement regarding a merger with AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit targets investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, and were entitled to vote on the merger [2] - The class has not yet been certified, meaning potential class members are not currently represented by an attorney [4] Group 2: Allegations Against Cerevel - Cerevel is accused of making false and misleading statements regarding its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024, related to AbbVie's acquisition at $45 per share [5] - The secondary stock offering was allegedly organized by Bain and Pfizer to increase Bain's investment at a discounted price, anticipating AbbVie's undisclosed acquisition plan [5] - The acquisition plan was publicly announced just 51 days after the secondary offering, at a price nearly double the offering price, leading to investor damages when the truth emerged [5]

Financial Performance & Outlook - Total revenues reached $492 million, exceeding the latest guidance, compared to $93 million in 2023, a 427% increase[25,59] - Product revenues were $273 million, surpassing $49 million in 2023, a 462% increase[25,59] - Adjusted EBITDA was $108 million, a significant turnaround from a loss of $291 million in 2023[25,59] - The company anticipates revenues between $570 million and $670 million in 2025, with product revenue contributing $340 million to $410 million and milestone revenues between $230 million and $260 million[67] - The company projects an adjusted EBITDA between $180 million and $260 million in 2025[67] - Alvotech targets approximately $1.5 billion in revenue by 2028[70,77] - Alvotech targets an EBITDA margin of 40-45% by 2028[73,77] Commercial & R&D Updates - SIMLANDI units shipped to the US across both branded and private label channels in 2024 reached 1.3 million, with 60% of those units shipped in Q4 2024[35] - The company has biosimilar approval in 63 markets and has launched in 29 markets[37] - By the end of 2025, investments will enable a total annual capacity of 15 million finished units[42]

Core Viewpoint - AbbVie has entered a licensing agreement with Gubra for an experimental weight loss drug, GUB014295, which is currently in Phase 1 trials, potentially positioning the company in a lucrative market projected to be worth $130 billion by 2030 [1][3][2] Group 1: Licensing Agreement and Financial Commitment - AbbVie made a $350 million upfront payment to Gubra for the rights to GUB014295 and has committed to pay up to $1.9 billion based on development and sales milestones [2] - Following the announcement, AbbVie stock has increased over 19% since the beginning of the year, indicating strong market sentiment [2] Group 2: Market Potential and Competitive Advantage - The weight loss drug market is currently dominated by Novo Nordisk's Ozempic and Eli Lilly's Zepbound, but GUB014295 offers a unique mechanism by acting as an analog of the body's amylin hormone, unlike the competitors that target the GLP-1 hormone [3][4] - GUB014295 has shown promising results in a six-week Phase 1 study, with patients achieving a 3% weight loss after a single dose [5] Group 3: Analyst Sentiment and Stock Valuation - AbbVie stock reached an all-time high of over $216 per share following the announcement but has since stabilized around $212 [9] - The trailing twelve-month P/E ratio is 88x, but the forward P/E is around 17x, suggesting the stock may be undervalued compared to its historical average [10] - Analysts from Bank of America and Wells Fargo have raised their price targets for AbbVie stock to $223 and $240, respectively, indicating positive outlooks [11]

Group 1 - AbbVie Inc. has entered the obesity treatment market by in-licensing GUB014295 (GUBamy) from Gubra, a Denmark-based company [2] - GUB014295 is a long-acting amylin analog aimed at treating obesity, indicating AbbVie's strategic expansion into a new therapeutic area [2]

Core Viewpoint - The upcoming January reading of the Personal Consumption Expenditure (PCE) index is expected to indicate persistent inflation, prompting investors to consider sectors that can benefit from inflation rather than fleeing the stock market entirely [1][2]. Inflation Overview - The PCE index is anticipated to confirm previous inflation readings from the Consumer Price Index (CPI) and Producer Price Index (PPI), suggesting inflation rates are likely to rise rather than approach the Federal Reserve's target [2]. - U.S. consumers now expect inflation to increase to 6% over the next 12 months, up from 5.2% [3]. Interest Rates Impact - Rising interest rates, implemented to combat inflation, have led to stock market volatility, particularly affecting technology stocks due to concerns over higher borrowing costs [3][4]. - There are indications that the Federal Reserve may need to raise rates again, delaying potential rate cuts [3]. Defensive Sectors to Watch - Defensive sectors are highlighted as potential investment opportunities, characterized by companies that provide essential products and services regardless of economic conditions [5][6]. - These sectors typically feature strong balance sheets and pricing power, allowing for solid earnings growth and dividends [5][6]. Biopharmaceuticals - The biopharmaceutical sector is divided into small-cap companies with high-risk profiles and blue-chip stocks like AbbVie and Merck, which offer value and growth potential due to their established drug portfolios and strong pipelines [7][9]. Consumer Staples - Consumer staples are expected to perform well in inflationary environments, with companies like PepsiCo and Mondelez showing pricing power and reliable dividends [11][12]. - Other notable companies in this sector include Procter & Gamble and Kimberly-Clark, which also exhibit similar attributes [13]. Utilities - Utility stocks are considered reliable investments due to their consistent demand, with NextEra Energy being a notable example [14][15]. Metals and Mining - Metals and mining stocks, particularly those related to gold and copper, are viewed as inflation hedges, with companies like Newmont and Freeport-McMoRan recommended for exposure to precious metals [16][17].

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-274094 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AEON Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 5 Park Plaza, Suite 1750 Irvin ...